Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care

키워드

참고문헌 (66)

1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
2. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
3. Margaret LP Teng, "Global incidence and prevalence of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.32~42 (2023), 대한간학회
4. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
5. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
6. Simon TG, "Mortality in biopsy-confirmed nonalcoholic fatty liver disease : results from a nationwide cohort", Gut, 70, pp.1375~1382 (2021)
7. Bilson J, "Non-alcoholic fatty liver disease : a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function", Proc Nutr Soc, 81, pp.146~161 (2022)
8. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
9. Nakahara T, "Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients", J Gastroenterol, 49, pp.1477~1484 (2014)
10. American Diabetes Association, "4. Comprehensive medical evaluation and assessment of comorbidities : standards of medical care in diabetes-2019", Diabetes Care, 42(Suppl 1), pp.S34~S45 (2019)
11. Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
12. ElSayed NA, "Summary of revisions : standards of care in diabetes-2023", Diabetes Care, 46(Suppl 1), pp.S5~S9 (2023)
13. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
14. Saisai Zhang, "Screening strategy for non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 29, pp.103~122 (2023), 대한간학회
15. Alexander M, "Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD : real-world study of 18 million patients in four European cohorts", BMC Med, 17, pp.95~ (2019)
16. Younossi ZM, "Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U. S", Diabetes Care, 43, pp.283~289 (2020)
17. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
18. Yoneda M, "Combination of tofogliflozin and pioglitazone for NAFLD : extension to the ToPiND randomized controlled trial", Hepatol Commun, 6, pp.2273~2285 (2022)
19. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
20. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.56, 951~963
21. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.51, 1013~1025
22. Targher G, "Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients", Diabetes, 54, pp.3541~3546 (2005)
23. Yoneda M, "Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view : a retrospective nationwide claims database study in Japan", J Gastroenterol, 56, pp.1022~1032 (2021)
24. Lonardo A, "Hypertension, diabetes, atherosclerosis and NASH : cause or consequence?", J Hepatol, 68, pp.335~352 (2018)
25. Lee YH, "Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients", J Hepatol, 68, pp.764~772 (2018)
26. Canada JM, "Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance", Am J Cardiol, 123, pp.466~473 (2019)
27. Byrne CD, "NAFLD as a driver of chronic kidney disease", J Hepatol, 72, pp.785~801 (2020)
28. Yasui K, "Nonalcoholic steatohepatitis and increased risk of chronic kidney disease", Metabolism, 60, pp.735~739 (2011)
29. Targher G, "Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease", J Am Soc Nephrol, 19, pp.1564~1570 (2008)
30. Sinn DH, "Development of chronic kidney disease in patients with non-alcoholic fatty liver disease : a cohort study", J Hepatol, 67, pp.1274~1280 (2017)
31. Jung CY, "Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease", Diabetologia, 65, pp.518~527 (2022)
32. Heerspink HJ, "Dapagliflozin in patients with chronic kidney disease", N Engl J Med, 383, pp.1436~1446 (2020)
33. Tomeno W, "Non-alcoholic fatty liver disease comorbid with major depressive disorder : the pathological features and poor therapeutic efficacy", J Gastroenterol Hepatol, 30, pp.1009~1014 (2015)
34. Kim D, "Depression is associated with non-alcoholic fatty liver disease among adults in the United States", Aliment Pharmacol Ther, 50, pp.590~598 (2019)
35. Xiao J, "Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease", Front Med (Lausanne), 8, pp.691696~ (2021)
36. Koreki A, "Risk of nonalcoholic fatty liver disease in patients with schizophrenia treated with antipsychotic drugs : a crosssectional study", J Clin Psychopharmacol, 41, pp.474~477 (2021)
37. Hidese S, "Association of depression with body mass index classification, metabolic disease, and lifestyle : a web-based survey involving 11, 876 Japanese people", J Psychiatr Res, 102, pp.23~28 (2018)
38. Koo BK, "Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis", J Hepatol, 66, pp.123~131 (2017)
39. Petta S, "Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 45, pp.510~518 (2017)
40. Keating SE, "Exercise and non-alcoholic fatty liver disease : a systematic review and meta-analysis", J Hepatol, 57, pp.157~166 (2012)
41. Hashida R, "Aerobic vs. resistance exercise in non-alcoholic fatty liver disease : a systematic review", J Hepatol, 66, pp.142~152 (2017)
42. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
43. Orci LA, "Exercise-based interventions for nonalcoholic fatty liver disease : a meta-analysis and meta-regression", Clin Gastroenterol Hepatol, 14, pp.1398~1411 (2016)
44. Brouwers B, "Effects of exercise training on intrahepatic lipid content in humans", Diabetologia, 59, pp.2068~2079 (2016)
45. Bellentani S, "Behavior therapy for nonalcoholic fatty liver disease : the need for a multidisciplinary approach", Hepatology, 47, pp.746~754 (2008)
46. Williams RC, "Periodontal medicine : the emergence of a new branch of periodontology", Periodontol 2000, 23, pp.9~12 (2000)
47. Furuta M, "Relationship between periodontitis and hepatic abnormalities in young adults", Acta Odontol Scand, 68, pp.27~33 (2010)
48. Yoneda M, "Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease", BMC Gastroenterol, 12, pp.16~ (2012)
49. Alakhali MS, "The potential association between periodontitis and non-alcoholic fatty liver disease : a systematic review", Clin Oral Investig, 22, pp.2965~2974 (2018)
50. Weintraub JA, "Oral diseases associated with nonalcoholic fatty liver disease in the United States", J Dent Res, 98, pp.1219~1226 (2019)
51. Iwasaki T, "Correlation between ultrasound-diagnosed non-alcoholic fatty liver and periodontal condition in a cross-sectional study in Japan", Sci Rep, 8, pp.7496~ (2018)
52. Nakahara T, "Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease", J Gastroenterol, 53, pp.269~280 (2018)
53. Kamata Y, "Periodontal treatment and usual care for nonalcoholic fatty liver disease : a multicenter, randomized controlled trial", Clin Transl Gastroenterol, 13, pp.e00520~ (2022)
54. Yoneda M, "What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?", Expert Opin Pharmacother, 22, pp.1217~1220 (2021)
55. Romero-Gómez M, "Treatment of NAFLD with diet, physical activity and exercise", J Hepatol, 67, pp.829~846 (2017)
56. Boden G, "High-or low-carbohydrate diets : which is better for weight loss, insulin resistance, and fatty livers?", Gastroenterology, 136, pp.1490~1492 (2009)
57. Haufe S, "Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects", Hepatology, 53, pp.1504~1514 (2011)
58. Sacks FM, "Comparison of weightloss diets with different compositions of fat, protein, and carbohydrates", N Engl J Med, 360, pp.859~873 (2009)
59. Song J, "Association of plasma 7-ketocholesterol with cardiovascular outcomes and total mortality in patients with coronary artery disease", Circ Res, 120, pp.1622~1631 (2017)
60. Chang J, "Dietary oxysterol, 7-ketocholesterol accelerates hepatic lipid accumulation and macrophage infiltration in obese mice", Front Endocrinol(Lausanne), 11, pp.614692~ (2021)
61. Ryan MC, "The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease", J Hepatol, 59, pp.138~143 (2013)
62. Zhu Y, "Dietary total fat, fatty acids intake, and risk of cardiovascular disease : a dose-response meta-analysis of cohort studies", Lipids Health Dis, 18, pp.91~ (2019)
63. Alrasheed M, "The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States", Qual Life Res, 31, pp.2481~2491 (2022)
64. Sumida Y, "Current and future pharmacological therapies for NAFLD", NASH, 2018, pp.53, 362~376
65. Bessone F, "Review article : drug-induced liver injury in the context of nonalcoholic fatty liver disease : a physiopathological and clinical integrated view", Aliment Pharmacol Ther, 48, pp.892~913 (2018)
66. Sungchul Choi, "Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study", Clinical and Molecular Hepatology, 29(2), pp.433~452 (2023), 대한간학회

관련 논문AI추천